Lifecore Biomedical Inc Stock Price, News & Analysis

Lifecore Biomedical (NASDAQ: LFCR) reported revenue of $31.1 million for the three months ended September 30, 2025, a 26% increase versus the comparable prior period, and recorded a net loss of $10.0 million (loss per diluted share $0.29).

Gross profit rose to $7.8 million. Adjusted EBITDA improved to $3.1 million from negative $1.8 million a year earlier. SG&A expense declined by $5.9 million. Interest expense increased to $6.3 million, partly due to Alcon term loan PIK interest and debt discount amortization.

The company signed multiple new programs, improved manufacturing productivity by 20%+, plans an ERP go-live in Q1 2026, and affirmed transition-period guidance of revenue $74–76M, net loss $16.4–18.4M, and Adjusted EBITDA $12–14M.

Lifecore Biomedical (NASDAQ: LFCR) will report financial results for the three months ended September 30, 2025 on Thursday, November 6, 2025 after market close.

Management will host a live webcast at 4:30 p.m. Eastern Time the same day to discuss results. To listen live or access the archived webcast (available for 30 days), visit the company’s Investor Events & Presentations page: https://ir.lifecore.com/events-presentations.

Lifecore Biomedical (NASDAQ: LFCR) announced on October 29, 2025 that it signed an agreement to execute a commercial site transfer and become the commercial supplier of choice for a leading injectable pharmaceutical product after regulatory requirements are satisfied. This is the second agreement with the same multinational customer in recent months. Lifecore also signed a separate pre-clinical formulation development agreement with an early-stage biotech, expanding its early-stage pipeline.

The deals are positioned to increase capacity utilization, broaden the commercial customer base, and leverage Lifecore’s fill-finish and regulatory track record as a U.S.-based CDMO for sterile injectables.

Lifecore Biomedical (NASDAQ: LFCR) and PolyPeptide announced a collaboration on October 28, 2025 to deliver an integrated end-to-end peptide manufacturing solution for the U.S. market.

The agreement pairs PolyPeptide’s peptide drug substance (DS) development and manufacturing capabilities with Lifecore’s formulation, fill/finish, and packaging expertise to enable a seamless DS-to-drug product (DP) transition, with the stated goals of accelerating development timelines, lowering development costs and risks, and providing a fully U.S.-based supply chain with aligned regulatory oversight.

Lifecore Biomedical (NASDAQ: LFCR) will participate at three industry events in Oct–Nov 2025 to engage customers and partners and present expertise in process development.

Events & details: PODD Conference (Boston) Oct 27–28 — Ryan Swanson, Ph.D., will join a panel titled "Achieving Effective Manufacturing Scaleup for Clinical and Commercial Success" on Oct 28 at 3:35–4:05 p.m. ET; booth 601. CPHI Worldwide (Frankfurt) Oct 28–30 — business development presence; booth 5.0B110. American Pharma Manufacturing & Outsourcing Summit (Boston) Nov 17–18 — business development presence; booth TBD.

For meetings contact info@lifecore.com or Lifecore on LinkedIn and see https://www.lifecore.com/events/ for booth links.

Lifecore Biomedical (NASDAQ: LFCR), a contract development and manufacturing organization (CDMO), has announced equity inducement grants for a newly hired employee. The compensation committee approved 15,000 restricted stock units (RSUs) and stock options for 30,000 shares on September 22, 2025.

The RSUs will fully vest after three years, while the stock options will vest one-third after the first year and 1/36th monthly thereafter. The stock options have a seven-year term and an exercise price at Fair Market Value. These grants were made under Lifecore's Equity Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Lifecore Biomedical (NASDAQ: LFCR), a contract development and manufacturing organization (CDMO), announced its participation in the 24th Annual Contract Pharma Contracting and Outsourcing Conference as a Gold Sponsor. The event will take place on September 18-19, 2025, in New Brunswick, NJ.

The company will showcase its injectables development and manufacturing expertise at Table 35, highlighting its 40+ year track record and state-of-the-art isolator-based filling capacity. This participation aligns with Lifecore's three-pronged growth strategy focused on expanding existing customer relationships, advancing late-stage development portfolio, and attracting new business.

Lifecore Biomedical (NASDAQ: LFCR), a contract development and manufacturing organization (CDMO), has announced its participation in three upcoming investor conferences in September 2025.

The company will participate in the Morgan Stanley Global Healthcare Conference (Sept 8-10) featuring a fireside chat, the Barrington Research Virtual Fall Investment Conference (Sept 16), and the Jefferies CDMO Summit (Sept 17). The Morgan Stanley fireside chat will be webcast live and available for replay on Lifecore's investor website.

Lifecore Biomedical (NASDAQ: LFCR) reported its Q4 and fiscal year 2025 results, achieving $128.9 million in FY2025 revenue, meeting guidance. The company signed nine new programs with new customers during FY2025, expanding beyond ophthalmic therapeutics. Q4 revenue was $36.4 million, down 4% year-over-year, with a net loss of $1.1 million.

Key developments include operational efficiency improvements, new leadership implementation, and plans to align fiscal year-end with the calendar year by December 31, 2025. The company maintains its commitment to achieving a 12%+ revenue CAGR and expanding adjusted EBITDA margins to over 25% in the mid-term. For the seven-month transition period through December 2025, Lifecore projects revenue of $74-76 million and adjusted EBITDA of $12-14 million.